Evogene Ltd. · NASDAQ:EVGN
Evogene — Q4 2024 Earnings Presentation
33 slides from Evogene's earnings presentation, Mar 6, 2025

Slide 1: Q4 2024 Earnings Call
Exhibit 99.2 Q42024EARNINGSCALLOFERHAVIV|PRESIDENT&CEOMarch06,2025

Slide 2: Forward-looking statements
Thispresentationcontains"forward-lookingstatements"relatingtofutureevents,andEvogeneLtd.(the“Company”),mayfromtimetotimemakeotherstatements,regardingouroutlookorexpectationsforfuturefinancialoroperatingresultsand/orothermattersregardingoraffectingusthatareconsidered“forward-lookingstatements”asdefin

Slide 3: Earnings Call Q4 2024 Agenda
EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A3CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

Slide 4: CEO Update: New Chairman Nir Nimrodi
44CEOUPDATEMr.NirNimrodihasservedasSpecialAdvisortotheEvogeneboardsince2020,andfromSeptember2022asaboardmember.Mr.Nimrodibrings25yearsofdiverseinternationalexperienceinbothstart-upsandlargeglobalbusinessesinthelifescience,pharmaceutical,andbiotechnologyindustries.Mr.NimrodiwastheChairmanandCEOofAcce

Slide 5: Agenda: Financial & Business Highlights
EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A5CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

Slide 6: CEO Update: Financial Highlights - Revenues
66CEOUPDATEFinancialHighlights:Intheyear2024,totalrevenuesreachedapproximately$8.5millioncomparedto$5.6millionintheyear2023.Theincreaseinrevenuesinyear2024,ismainlyduetoincreaseinAgPlenus'revenuesfromitscollaborationwithBayerandanincreaseinCasterra’sseedsales.InQ4of2024,totalrevenuesreachedapproxima

Slide 7: CEO Update: Financial Highlights - Expenses
77CEOUPDATEFinancialHighlights:Intheyear2024,totalR&Dexpenseswereapproximately$16.6millioncomparedto$20.8millionintheyear2023.InQ4of2024,totalR&Dexpenseswereapproximately$3.4millioncomparedto$5.5millioninQ42023.ThesedecreasesaremainlyduetotheendofCanonic'sactivityinQ22024andadecreaseinBiomica'sandLa

Slide 8: CEO Update: Business Highlights 2024 to date
88CEOUPDATEBusinessHighlights2024todate:EvogeneOct.2024,collaborationwithGoogleCloudtopioneergenerativeAIfoundationmodelfornovelsmallmoleculedesign.CasterraDuring2024,Casterradeliveredtoitspartner~215tonsofcastorseeds,~76tonsinQ42024.InFebruary2025Casterradeliveredtoitspartner~250tonsofcastorseeds.C

Slide 9: Business Highlights 2024 to date: Lavie Bio and AgPlenus
BusinessHighlights2024todate:LavieBioFeb.2024,newcollaborationagreementwithSyngentatodiscoveranddevelopnovelbio-insecticides.July2024,ICLandLavieBioachievedasignificantmilestoneintheircollaboration,developingyield-increasingbio-stimulantsforrowcropsunderextremeweatherconditionsbyleveragingAItoidenti

Slide 10: Agenda: Evogene Overview
EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A10CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

Slide 11: Our Vision and Mission
OURVISIONPIONEERGROUNDBREAKINGLIFE-SCIENCEPRODUCTSROOTEDINMICROBES,SMALLMOLECULES,ANDGENOMICSDECODINGBIOLOGY11OURMISSIONWEMERGELIFE-SCIENCEWITHBIGDATAANDCUTTING-EDGEAITECHNOLOGIESTOEFFECTIVELYDISCOVERANDOPTIMIZEBREAKTHROUGHLIFE-SCIENCEBASEDPRODUCTS

Slide 12: Discovery & Optimization through 3 AI tech-engines
DISCOVERY&OPTIMIZATIONWEDIRECTANDACCELERATELIFE-SCIENCEPRODUCTthrough3dedicatedAItech-enginesMICROBESGENETICELEMENTSSMALLMOLECULESTheResult:Promisingcandidatesaddressingmultipledevelopmentchallengestowardssuccessfullife-science-basedproducts.PROBABILITYOFSUCCESSTIMECOST12

Slide 13: A World of Opportunities for Our AI Tech Engines
13SMALLMOLECULESGENETICELEMENTSMICROBESAWORLDOFOPPORTUNITIESFOROURAITECHENGINESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESImprovedcropsAlternativefoodMedicalCannabisGenetherapyDiagnostics&precisionmedicineCelltherapyBiofuelFragrancesNaturalfoodcoloringNovelenzymesAGRICULTURE&FOODPHARMA&WELLNESSOT

Slide 14: Business Strategy
14BUSINESSSTRATEGYCapturethevalueofourAItech-enginesthroughdiversecollaborativepartnershipstoacceleratelife-scienceproductdevelopmentPartneringwithexpertsinspecificfieldscomplementsourtechnology,enablinggroundbreakinginnovationsandfinancialgainsforEvogene.EVOGENEAITechEnginesNovelLife-ScienceProduct

Slide 15: Licensing & Collaboration Current Status
AquacultureLicensingCollaborationImprovedcropsCropprotectionPharmaceuticalsMicrobialsforcropsTherapeuticmicrobials15LICENSING&COLLABORATION|CURRENTSTATUSFood-TechAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIES

Slide 16: Commercial & Financial Partners
16GroupCOMMERCIAL&FINANCIALPARTNERSInvestment&CollaborationCollaborationInvestment&CollaborationCollaborationCollaborationInvestmentCollaborationCollaborationCollaborationCollaborationCollaboration

Slide 17: Looking into 2025-2026
1717LOOKINGINTO2025-2026EvogeneFocusonenhancingChemPassAItech-engine’scompetitiveadvantageforthepharmamarketsegment(ex.-buildingfoundationmodelwithGoogleCloud).Engageincollaborationswithbio-techandacademiaforsmall-moleculedrugdiscovery,utilizingChemPassAI.ContinuethesupportanddevelopmentofMicroBoost

Slide 18: Drug Development Based on Small Molecules
SMALLMOLECULESGENETICELEMENTSMICROBESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESImprovedcropsAlternativefoodMedicalCannabisGenetherapyDiagnostics&precisionmedicineCelltherapyBiofuelFragrancesNaturalfoodcoloringNovelenzymesAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESCropprotectionChemicalstimula

Slide 19: Why Pharma?
TheChallenge:Discoveringtherightsmallmoleculeislikefindinganeedleinahaystack.TheRewards:Asolutionoffersthepotentialforsignificantfinancialimpact.TheAIRevolution:AIenablesthediscoveryandoptimizationofsmallmoleculecandidates,addressingmultipledevelopmentrequirementsforasuccessfuldrug.Thisapproachaddre

Slide 20: Multi-Million Agreements with Global Pharma
MULTI-MILLIONAGREEMENTSWITHGLOBALPHARMA20

Slide 21: Why Evogene?
WHYEVOGENE?MultidisciplinaryExpertiseIntegratingchemistry,biology,andAIforoptimizeddrugdiscoveryCollaborativePartnershipProvenabilitytoworkwithpartners,totranslatecomputationalpredictionsintoreal-worlddrugcandidatesAI-FirstApproachInternalcapabilitiestodevelopproprietymachinelearninganddeeplearninga

Slide 22: Discussions with Potential Partners
22AUSTRALIACANADASOUTHKOREAISRAELGERMANYUKDISCUSSIONSWITHPOTENTIALPARTNERSUSA

Slide 23: Agenda: Subsidiaries' 2025 Targets
EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A23CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

Slide 24: Casterra: Main Targets for 2025
24Casterrafocusesondevelopingintegratedsolutionsforlarge-scalecastorbeanfarming,utilizingGeneRatorAItech-enginePoweredbyMaintargetsfor2025IncreasecastorseedsrevenueinAfricawithinitialsalesinBrazilandadditionalterritories.InitiatePOCtrialsforgrainfarmingforoilproduction,withatier1partnerinKenyaorBraz

Slide 25: Lavie Bio: Main Targets for 2025
25LavieBio,agloballeaderindevelopingnextgenerationag-biologicalproducts,leveragingMicroBoostAItech-engineMaintargetsfor2025Engageinanewcollaborationagreementforfungicides(LAV311,LAV321).IncreaseYalos®revenuewithinitialsalesinsoybean.AchieveR&DmilestonesinICLcollaborationtowardcommercialagreement.Ach

Slide 26: AgPlenus: Main Targets for 2025
AgPlenusspecializesindevelopingnovelandsustainablecropprotectionproducts,utilizingEvogene’sChemPassAItech-enginePoweredby26Maintargetsfor2025Achieve2ndmilestoneinCortevacollaborationagreement.ExecuteBayerherbicidecollaborationaccordingtoworkplan.Discoverandadvance2-3smallmolecules(hits)withnewMoAsin

Slide 27: Biomica: Main Targets for 2025
27Biomicaspecializesindevelopingmicrobiome-basedtherapeuticsforhumanhealth,utilizingEvogene'sMicroBoostAItech-enginePoweredbyMaintargetsfor2025CompletePhase1studyinoncologyprogram;obtainfullresultsandadditionalsupportingclinicaldata.SubmitINDapplicationtotheUSFDAandobtainFDAapprovalforthePhase2study

Slide 28: Agenda: CFO Update
EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A28CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

Slide 29: CFO Update: Consolidated Statements of Financial Position (Assets)
CFO UPDATE evOgene CONSOLIDATED STATEMENTS OF FINANCIAL POSITION US. dollars in thousands CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Trade receivables Other receivables and prepaid expenses Deferred expenses related to issuance of warrants Inventories LONG-TERM ASSETS: Long-t

Slide 30: CFO Update: Liabilities and Shareholders' Equity
CFO UPDATE December 31, December 31, 2024 2023 CURRENT LIABILITIES: Trade payables $ 1,228 $1,785 Employees and payroll accruals 1,869 2,537 Lease liability 589 853 Liabilities in respect of government grants 323 388 Deferred revenues and other advances 360 362 ‘Warrants and pre-funded warrants liab

Slide 31: Evogene Financial Performance 2024 and Q4 2024
CFOUPDATEEvogeneFinancialPerformance2024andQ4202431

Slide 32: Agenda: Q&A
EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A32CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

Slide 33: Thank You
ev gene = THANK YOU
Source: 6ix earnings call
More decks from Evogene Ltd.
Investor Presentation (August 2026)32 slides · Aug 27, 2026
Q2 2026 Earnings Presentation18 slides · Aug 18, 2026
Investor Presentation (June 2026)32 slides · Jun 16, 2026
Q1 2026 Earnings Presentation27 slides · May 20, 2026
Investor Presentation (April 2026)27 slides · Apr 28, 2026
Investor Presentation (March 2026)26 slides · Mar 12, 2026